flurbiprofen has been researched along with Cognition Disorders in 3 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
Cognition Disorders: Disorders characterized by disturbances in mental processes related to learning, thinking, reasoning, and judgment.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abdul-Hay, SO | 1 |
| Luo, J | 1 |
| Ashghodom, RT | 1 |
| Thatcher, GR | 1 |
| Green, RC | 1 |
| Schneider, LS | 1 |
| Amato, DA | 1 |
| Beelen, AP | 1 |
| Wilcock, G | 1 |
| Swabb, EA | 1 |
| Zavitz, KH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type[NCT00105547] | Phase 3 | 1,600 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease[NCT03277573] | Phase 1 | 40 participants (Anticipated) | Interventional | 2017-07-21 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for flurbiprofen and Cognition Disorders
| Article | Year |
|---|---|
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
2 other studies available for flurbiprofen and Cognition Disorders
| Article | Year |
|---|---|
NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.
Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Avoidance Learning; Cell Line, Tumor | 2009 |
Disease-modifying drug fails in Alzheimer's study.
Topics: Activities of Daily Living; Alzheimer Disease; Amyloid Precursor Protein Secretases; Cognition; Cogn | 2010 |